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Supplementary Table 1. Primary cause of graft loss or death by transplant type†   
 
 LDLT DDLT 
 (n= 44) (n= 44) 
  n (%) n (%) 
Recurrent HCV 12 (27%) 9 (20%) 
Biliary complication 1 (2%) 3 (7%) 
Cardiovascular disease 3 (7%) 5 (11%) 
Infection 2 (5%) 8 (18%) 
Malignancy 9 (20%) 5 (11%) 
Vascular complications 1 (2%) 0 (0%) 
Other* 16 (36%) 14 (32%) 
†All p-values comparing LDLT versus DDLT are not significant (smallest p=0.09 for infection; for recurrent HCV 
p=0.45). 
*Other causes include respiratory failure, hemorrhage, thrombosis, cholestasis, and unknown. 
 
Abbreviations: HCV=hepatitis C virus; LDLT=living donor liver transplant; DDLT=deceased donor liver transplant 
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Supplementary Table 2. Predictors of cirrhosis (using histological and clinical data) 
 
  Single Variable Model Multivariable Model 
Predictors HR 95% CI p-value HR 95% CI p-value 
LDLT vs. DDLT 1.33 0.77-2.29 0.3089 1.37 0.76-2.46 0.2891 
AST at transplant (log2 IU/L) 1.75 1.3-2.35 0.0002 1.91 1.39-2.63 0.0001 
ALT at transplant (per 100 IU/L) 1.36 1.05-1.77 0.0195 -- -- -- 
Biliary stricture complication† 1.94 1.07-3.51 0.0291 -- -- -- 
Donor age (per 10 years) 1.18 0.96-1.46 0.1203 1.25 0.99-1.57 0.0624 
       
† As a time-varying covariate 
 
Other predictors were tested and were not significant: recipient sex, recipient age, recipient race, recipient 
ethnicity, recipient BMI, recipient weight, donor sex, donor race, warm ischemia time, cold ischemia time, 
alkaline phosphatase, bilirubin, INR, creatinine, MELD, HCC diagnosis, diabetes status, steroid and tacrolimus 
use at transplant or within 10 days post-transplant, and HCV treatment, treatment for acute rejection, and biliary 
leak complication as time-varying covariates. 
 
Abbreviations: LDLT=living donor liver transplant; DDLT=deceased donor liver transplant; AST=aspartate 
aminotransferase; ALT=alanine aminotransferase; BMI=body mass index; MELD=Model for End-Stage Liver 
Disease; HCC=hepatocellular carcinoma; HCV=hepatitis C virus 
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Supplementary Table 3a. Donor risk index (DRI) as potential predictor of advanced fibrosis 
 
Predictor N in DRI Group HR 95% CI p-value 
DDLT with DRI missing vs LDLT 34 1.15 0.48 - 2.73 0.76 
0 < DRI < 1.2 vs LDLT 36 0.38 0.12 - 1.23 0.11 
1.2 ≤ DRI < 1.4 vs LDLT 34 1.29 0.63 - 2.46 0.49 
1.4 ≤ DRI < 1.8 vs LDLT 45 0.70 0.36 - 1.39 0.31 
DRI ≥ 1.8 vs LDLT 31 1.39 0.66 - 2.96 0.39 
Abbreviations: DDLT=deceased donor liver transplant; LDLT=living donor liver transplant 
Note: Adjusted for AST at transplant, biliary stricture, and donor age. 
 
 
Supplementary Table 3b. Donor risk index (DRI) as potential predictor of graft loss 
 
Predictor N in DRI Group HR 95% CI p-value 
DDLT with DRI missing vs LDLT 34 0.93 0.39 - 2.22 0.89 
0 < DRI < 1.2 vs LDLT 36 0.79 0.33 - 1.92 0.61 
1.2 ≤ DRI < 1.4 vs LDLT 34 0.85 0.33 - 2.20 0.73 
1.4 ≤ DRI < 1.8 vs LDLT 45 1.70 0.93 - 3.11 0.08 
DRI ≥ 1.8 vs LDLT 31 2.49 1.26 - 4.92 0.01 
Abbreviations: DDLT=deceased donor liver transplant; LDLT=living donor liver transplant 
Note: Adjusted for creatinine at transplant, AST at transplant, and biliary stricture. 
 
 
 
 





